Similar Search Results

A Panel Data Study of Physicians’ Labor Supply: The Case of Norway

Baltagi, Badi H.; Bratberg, Espen; Holmås, Tor Helge - CESifo - 2003

Physicians are key personnel in a sector which is important due to its size as well as the quality of service it … provides. We estimate the labor supply of physicians employed at hospitals in Norway, using personnel register data merged with … other public records. A dynamic labor supply equation is estimated using a sample of 1303 physicians observed over the …

Persistent link: https://www.econbiz.de/10005766301

Is Medicines Parallel Trade ‘Regulatory Arbitrage’?

Costa-i-Font, Joan - CESifo - 2015

In the European Union, medicines are regulated products subject to both single market (e.g., regional exhaustion of property rights) and country specific health care regulations (e.g., medicines pricing and distribution regulation). This gives rise to parallel trade (PT), a phenomenon that takes...

Persistent link: https://www.econbiz.de/10011274346

Choosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?

Dalen, Dag Morten; Sorisio, Enrico; Strøm, Steinar - CESifo - 2010

TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 % of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...

Persistent link: https://www.econbiz.de/10008727300

Margins and Market Shares: Pharmacy Incentives for Generic Substitution

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - CESifo - 2012

generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

Persistent link: https://www.econbiz.de/10010603857

Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?

Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge - CESifo - 2007

-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …

Persistent link: https://www.econbiz.de/10005406112

Direct to Consumer Advertising in Pharmaceutical Markets

Brekke, Kurt R.; Kuhn, Michael - CESifo - 2005

is allowed, this can be employed to induce (additional) patient visits. Physicians perfectly observe the patients' type …), creating a captive and a selective segment of physicians. First, we show that detailing, DTCA and price (if not regulated) are …

Persistent link: https://www.econbiz.de/10005406241

Reference Pricing of Pharmaceuticals

Brekke, Kurt R.; Königbauer, Ingrid; Straume, Odd Rune - CESifo - 2006

We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry...

Persistent link: https://www.econbiz.de/10005406396

Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - CESifo - 2010

We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...

Persistent link: https://www.econbiz.de/10008799730

A Probability Approach to Pharmaceutical Demand and Price Setting: Does the Identity of the Third-Party Payer Mattersfor Prescribing Doctors?

Dalen, Dag Morten; Locatelli, Marilena; Sorisio, Enrico; … - CESifo - 2011

TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what...

Persistent link: https://www.econbiz.de/10009371358